UPDATE 1-Novartis drug combo cuts pancreatic tumour size
Wed Jun 24, 2009 11:58am EDT
* Afinitor and Sandostatin LAR promising in Phase II trial
* Afinitor is one of Novartis's most important new drugs
(Adds further details)
ZURICH, June 24 (Reuters) - A combination of two drugs from Novartis AG (NOVN.VX: Quote, Profile, Research, Stock Buzz) cut the size of pancreatic neuroendocrine tumours in more than 80 percent of patients in a mid-stage study, the Swiss group said on Wednesday. Patients who received a once-daily pill Afinitor in combination with Sandostatin LAR had no progression in their disease for a median of 16.7 months, according to results from the so-called RADIANT-1 study of 160 patients.
Afinitor is one of Novartis's most important new drugs and is being tested for use against several different types of cancer, which could help it achieve sales of more than $1 billion annually.
It works by blocking a protein known as mTOR and disrupting the growth, division and metabolism of cancer cells and is a key plank of Novartis's strategy to expand in cancer drugs.
A late stage trial evaluating Afinitor as a potential treatment option for patients with pancreatic neuroendocrine tumours is already underway, Novartis said.
Pancreatic neuroendocrine tumours are an uncommon form of the disease, a cancer formed from cells that have roles both in the endocrine and nervous systems
At the time of diagnosis nearly 60 percent of all patients have advanced disease, meaning the cancer has spread to other parts of the body and has become more difficult to treat.
The U.S. Food and Drug Administration approved Afinitor earlier this year for use in advanced kidney cancer and European regulators have also recommended it. Novartis expects a filing for use in neuroendocrine tumours within the next year.
Sandostatin LAR is already approved for symptom control in certain types of neuroendocrine tumours. (Reporting by Sam Cage; Editing by Greg Mahlich)
© Thomson Reuters 2009. All rights reserved. Users may download and print extracts of content from this website for their own personal and non-commercial use only. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters and its logo are registered trademarks or trademarks of the Thomson Reuters group of companies around the world.